SEC Comment Letter 0000000000-24-001597 to Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc.
Date: Feb. 9, 2024 · CIK: 0001659617 · Accession: 0000000000-24-001597
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276851
Letter
United States securities and exchange commission logo February 9, 2024 Walter V. Klemp Chief Executive Officer and Chairman Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, Texas 77007 Re:Moleculin Biotech, Inc. Registration Statement on Form S-1 Filed February 2, 2024 File No. 333-276851 Dear Walter V. Klemp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas S. Pavri
Show Raw Text
United States securities and exchange commission logo
February 9, 2024
Walter V. Klemp
Chief Executive Officer and Chairman
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, Texas 77007
Re:Moleculin Biotech, Inc.
Registration Statement on Form S-1
Filed February 2, 2024
File No. 333-276851
Dear Walter V. Klemp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cavas S. Pavri